Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Halozyme Therapeutics Inc (NASDAQ: HALO) closed the day trading at $72.96 up 1.80% from the previous closing price of $71.67. In other words, the price has increased by $1.80 from its previous closing price. On the day, 1.34 million shares were traded. HALO stock price reached its highest trading level at $74.08 during the session, while it also had its lowest trading level at $71.37.
Ratios:
For a better understanding of HALO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.24. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 1.59.
On October 14, 2025, Leerink Partners Upgraded its rating to Market Perform which previously was Underperform but kept the price unchanged to $70.
Morgan Stanley Upgraded its Equal-Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $75.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’26 when Connaughton Bernadette sold 2,000 shares for $70.25 per share. The transaction valued at 140,500 led to the insider holds 40,123 shares of the business.
BERNADETTE CONNAUGHTON bought 2,000 shares of HALO for $140,620 on Jan 05 ’26. On Nov 01 ’25, another insider, Caudill Cortney, who serves as the SVP, CHIEF OPERATING OFFICER of the company, sold 4,263 shares for $65.19 each. As a result, the insider received 277,905 and left with 12,737 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8579876864 and an Enterprise Value of 9416772608. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.34, and their Forward P/E ratio for the next fiscal year is 8.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.90 while its Price-to-Book (P/B) ratio in mrq is 17.02. Its current Enterprise Value per Revenue stands at 7.577 whereas that against EBITDA is 11.579.
Stock Price History:
The Beta on a monthly basis for HALO is 0.97, which has changed by 0.2943833 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $47.50. The 50-Day Moving Average of the stock is 6.58%, while the 200-Day Moving Average is calculated to be 14.01%.
Shares Statistics:
Over the past 3-months, HALO traded about 2.21M shares per day on average, while over the past 10 days, HALO traded about 2083280 shares per day. A total of 117.52M shares are outstanding, with a floating share count of 116.26M. Insiders hold about 1.13% of the company’s shares, while institutions hold 102.95% stake in the company. Shares short for HALO as of 1767139200 were 13800472 with a Short Ratio of 6.23, compared to 1764288000 on 12372896. Therefore, it implies a Short% of Shares Outstanding of 13800472 and a Short% of Float of 16.350001.
Earnings Estimates
Halozyme Therapeutics Inc (HALO) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.83, with high estimates of $1.97 and low estimates of $1.68.
Analysts are recommending an EPS of between $6.39 and $6.18 for the fiscal current year, implying an average EPS of $6.25. EPS for the following year is $8.21, with 4.0 analysts recommending between $8.93 and $7.51.
Revenue Estimates
7 analysts predict $394.63M in revenue. The current quarter. It ranges from a high estimate of $417M to a low estimate of $373.1M. As of. The current estimate, Halozyme Therapeutics Inc’s year-ago sales were $298.01MFor the next quarter, 7 analysts are estimating revenue of $370.01M. There is a high estimate of $399.24M for the next quarter, whereas the lowest estimate is $353M.
A total of 8 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.36B, while the lowest revenue estimate was $1.32B, resulting in an average revenue estimate of $1.34B. In the same quarter a year ago, actual revenue was $1.02BBased on 7 analysts’ estimates, the company’s revenue will be $1.69B in the next fiscal year. The high estimate is $1.78B and the low estimate is $1.61B.
